Allied Biotech Corporation
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharm… Read more
Allied Biotech Corporation (1780) - Net Assets
Latest net assets as of September 2025: NT$1.19 Billion TWD
Based on the latest financial reports, Allied Biotech Corporation (1780) has net assets worth NT$1.19 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.30 Billion) and total liabilities (NT$1.11 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.19 Billion |
| % of Total Assets | 51.6% |
| Annual Growth Rate | 0.67% |
| 5-Year Change | 4.39% |
| 10-Year Change | N/A |
| Growth Volatility | 4.99 |
Allied Biotech Corporation - Net Assets Trend (2019–2024)
This chart illustrates how Allied Biotech Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Allied Biotech Corporation (2019–2024)
The table below shows the annual net assets of Allied Biotech Corporation from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.20 Billion | +2.29% |
| 2023-12-31 | NT$1.17 Billion | -1.25% |
| 2022-12-31 | NT$1.18 Billion | +9.44% |
| 2021-12-31 | NT$1.08 Billion | -5.57% |
| 2020-12-31 | NT$1.15 Billion | -0.94% |
| 2019-12-31 | NT$1.16 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allied Biotech Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$146.55 Million | 12.26% |
| Common Stock | NT$960.24 Million | 80.32% |
| Other Components | NT$88.74 Million | 7.42% |
| Total Equity | NT$1.20 Billion | 100.00% |
Allied Biotech Corporation Competitors by Market Cap
The table below lists competitors of Allied Biotech Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seoho Electric Co.Ltd
KQ:065710
|
$48.28 Million |
|
Wallbridge Mining Company Limited
OTCQB:WLBMF
|
$48.32 Million |
|
Bluebird bio Inc
NASDAQ:BLUE
|
$48.34 Million |
|
Cinclus Pharma Holding AB (publ)
F:J8P
|
$48.34 Million |
|
Birko Birlesik Koyunlulular Mensucat Ticaret ve Sanayi AS
IS:BRKO
|
$48.27 Million |
|
Jindal Drilling And Industries Limited
NSE:JINDRILL
|
$48.26 Million |
|
Focus Home Interactive SA
F:0HF
|
$48.26 Million |
|
Theragen Etex Co.Ltd
KQ:066700
|
$48.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allied Biotech Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,168,788,000 to 1,195,531,000, a change of 26,743,000 (2.3%).
- Net income of 100,939,000 contributed positively to equity growth.
- Dividend payments of 81,417,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$100.94 Million | +8.44% |
| Dividends Paid | NT$81.42 Million | -6.81% |
| Other Changes | NT$7.22 Million | +0.6% |
| Total Change | NT$- | 2.29% |
Book Value vs Market Value Analysis
This analysis compares Allied Biotech Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$12.16 | NT$27.00 | x |
| 2020-12-31 | NT$11.96 | NT$27.00 | x |
| 2021-12-31 | NT$11.34 | NT$27.00 | x |
| 2022-12-31 | NT$12.36 | NT$27.00 | x |
| 2023-12-31 | NT$12.18 | NT$27.00 | x |
| 2024-12-31 | NT$12.41 | NT$27.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allied Biotech Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.44%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.51%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.89x
- Recent ROE (8.44%) is above the historical average (7.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 9.25% | 16.72% | 0.33x | 1.68x | NT$-8.72 Million |
| 2020 | 6.94% | 12.86% | 0.27x | 1.97x | NT$-35.06 Million |
| 2021 | 1.21% | 1.93% | 0.28x | 2.26x | NT$-95.11 Million |
| 2022 | 12.40% | 20.47% | 0.33x | 1.84x | NT$28.38 Million |
| 2023 | 8.33% | 13.52% | 0.35x | 1.78x | NT$-19.47 Million |
| 2024 | 8.44% | 12.51% | 0.36x | 1.89x | NT$-18.61 Million |
Industry Comparison
This section compares Allied Biotech Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,565,403,000
- Average return on equity (ROE) among peers: 4.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allied Biotech Corporation (1780) | NT$1.19 Billion | 9.25% | 0.94x | $48.27 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $415.70 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.11% | 0.48x | $159.99 Million |
| Maywufa Co Ltd (1731) | $1.41 Billion | 2.15% | 1.10x | $41.61 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.36 Billion | 2.77% | 0.13x | $179.96 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $23.77 Million |
| Easywell Biomedicals Inc. (1799) | $623.80 Million | -23.22% | 0.95x | $82.61 Million |
| LIWANLI Innovation Co Ltd (3054) | $897.52 Million | 5.08% | 0.06x | $51.25 Million |
| YungShin Global Holding Corp (3705) | $5.90 Billion | 12.21% | 0.47x | $295.98 Million |
| TTY Biopharm Co Ltd (4105) | $6.23 Billion | 17.56% | 0.54x | $484.94 Million |